# PRDM1 Gene: Structure, Function, and Clinical Significance
## Key Takeaways
- PRDM1 (BLIMP-1) is a master transcriptional repressor critical for terminal differentiation of B cells into plasma cells, effector T cells, and NK cells, acting via its PR domain and zinc finger array to recruit chromatin-modifying complexes like HDACs and G9a.
- In lymphoid malignancies such as ABC-DLBCL and ENKTCL, PRDM1 functions as a tumor suppressor and is frequently inactivated by deletions at 6q21, somatic mutations (e.g., R84X, C478Y), or promoter hypermethylation.
- PRDM1 plays a dual role in hepatocellular carcinoma: driving T-cell exhaustion in chronic viral infections (HBV/HCV) but acting as a tumor suppressor within HCC cells by repressing stem cell-related genes.
- PRDM1 is essential for maintaining pregnancy by regulating decidualization and is implicated in autoimmune disease susceptibility (e.g., SLE) and T-cell exhaustion during chronic infections and cancer.
- Therapeutic strategies targeting PRDM1 include demethylating agents (e.g., 5-azacytidine) to restore expression in lymphomas, and approaches to downregulate PRDM1 in T cells (e.g., CRISPRi, siRNA) to enhance anti-tumor immunity.
- Viral pathogens like EBV actively downregulate PRDM1 via microRNAs (e.g., EBV-miR-BHRF1-2) and epigenetic silencing, contributing to lymphomagenesis by blocking plasma cell differentiation.
---
## Executive Summary & Key Metadata
The **PRDM1** gene (PR domain zinc finger protein 1), encoding the protein **B lymphocyte-induced maturation protein 1 (BLIMP-1)**, is a master transcriptional regulator governing terminal differentiation in multiple immune lineages, particularly B lymphocytes (plasma cells), T lymphocytes, and natural killer (NK) cells. It functions primarily as a transcriptional repressor via its N-terminal PR domain and sequence-specific C-terminal zinc finger array, though context-dependent activation roles are documented. PRDM1 is a well-established tumor suppressor in aggressive lymphomas, including activated B-cell-like diffuse large B-cell lymphoma (ABC-DLBCL), extranodal NK/T-cell lymphoma (ENKTCL), and Burkitt lymphoma. Its expression is tightly controlled by epigenetic mechanisms, microRNAs, and competing transcription factor networks. Beyond oncology, PRDM1 is implicated in autoimmune disease susceptibility, atherosclerosis, pregnancy maintenance, and developmental morphogenesis.
| **Attribute** | **Detail** |
|---|---|
| **HGNC Symbol** | PRDM1 |
| **UniProt Accession** | O75626 |
| **Representative PDB ID** | true (structural models available; see Section 2) |
| **Chromosomal Locus** | 6q21 (GRCh38: chr6:106,217,263–106,240,268; minus strand) |
| **Primary Molecular Function** | Sequence-specific DNA-binding transcription factor; transcriptional repressor/activator; master regulator of terminal differentiation in B, T, and NK cells |
| **Disease & Pathology Associations** | ABC-DLBCL, ENKTCL, Burkitt lymphoma, primary CNS lymphoma, hepatocellular carcinoma, autoimmune diseases (SLE, rheumatoid arthritis), atherosclerosis, recurrent pregnancy loss, split hand/foot malformation, preeclampsia |
---
## 1. Genomic Locus, Chromosomal Organization & Isoforms
### 1.1 Chromosomal Location and Gene Architecture
PRDM1 is located on the long arm of chromosome 6 at cytogenetic band **6q21**. The human reference genome (GRCh38) places the gene between coordinates chr6:106,217,263 and chr6:106,240,268 on the minus strand. The gene spans approximately 23 kilobases of genomic DNA and comprises **7 coding exons** (exons 2–7) preceded by alternative first exons (exon 1α and exon 1β) that give rise to two major protein-coding isoforms: **PRDM1α** and **PRDM1β** [1]. The 6q21 region is a known fragile site and is recurrently deleted in multiple lymphoid malignancies, including DLBCL, ENKTCL, and NK-cell neoplasms [1, 1].
### 1.2 Promoter Architecture and Alternative First Exons
The PRDM1 locus contains two distinct promoters that drive expression of the α and β isoforms. The **PRDM1α promoter** is the canonical promoter, located immediately upstream of exon 1α, and is responsive to signals that induce terminal B-cell differentiation, including interleukin-21 (IL-21), lipopolysaccharide (LPS), and interferon-γ (IFN-γ). The **PRDM1β promoter** is located further upstream and is regulated independently. Romero-García et al. demonstrated that these two promoters exhibit differential epigenetic regulation in human multiple myeloma cells, with PRDM1β being regulated by distinct DNA methylation and histone modification patterns compared to PRDM1α [1]. Specifically, the PRDM1β promoter is hypomethylated and associated with active histone marks (H3K4me3, H3K27ac) in myeloma cells, whereas the PRDM1α promoter shows more variable methylation status. This differential regulation allows for context-specific expression of the two isoforms, which may have distinct functional consequences.
### 1.3 Transcription Factor Binding Sites and Enhancer Elements
The PRDM1 promoter and its downstream regulatory regions contain multiple conserved transcription factor binding sites. Kwon et al. identified an **IL-21 response element** located downstream of the Prdm1 gene that binds both **STAT3** and **IRF4** in a cooperative manner [1]. This element is essential for IL-21-induced PRDM1 expression in B cells and CD8+ T cells. The binding of STAT3 and IRF4 to this element is enhanced by IL-21 receptor signaling, which activates JAK kinases and leads to STAT3 phosphorylation and nuclear translocation.
In B cells, the transcription factor **Bach2** represses PRDM1 expression by binding to a specific regulatory region and recruiting **histone deacetylase 3 (HDAC3)** [1]. This Bach2-HDAC3 complex maintains histone deacetylation at the PRDM1 promoter, preventing transcriptional activation. Upon B-cell activation and differentiation signals, Bach2 expression is downregulated, relieving this repression and allowing PRDM1 expression to proceed. Tanaka et al. demonstrated that Bach2 and HDAC3 cooperate to maintain the repressed state of Prdm1 in B cells, and that disruption of this complex leads to premature plasma cell differentiation [1].
Additional regulatory elements include binding sites for **IRF4**, **SPI-B**, **PAX5** (which represses PRDM1 in mature B cells), and **FOXO1** [1]. The PRDM1 locus also contains a **super-enhancer** region that is active in plasma cells and is marked by high levels of H3K27ac and MED1 occupancy.
### 1.4 Alternative Splicing and Isoform Diversity
Alternative splicing of PRDM1 generates multiple transcript variants. The two principal isoforms are:
- **PRDM1α (canonical)**: Encoded by exons 1α through 7, producing a protein of 825 amino acids (UniProt O75626-1). This isoform contains the full complement of functional domains, including the PR domain and all five zinc fingers.
- **PRDM1β**: Encoded by exons 1β through 7, producing a protein of 794 amino acids (UniProt O75626-2). PRDM1β lacks the N-terminal 31 amino acids present in PRDM1α but retains the PR domain and zinc finger array.
The two isoforms exhibit differential expression patterns and may have distinct transcriptional activities. In multiple myeloma, PRDM1β is expressed at higher levels than PRDM1α in some cell lines, and the two isoforms show differential sensitivity to epigenetic drugs [1]. The PRDM1β isoform lacks a portion of the N-terminal regulatory region, which may affect its interaction with co-repressor complexes.
Additional splice variants have been reported, including transcripts that skip exon 3 or exon 5, potentially generating truncated proteins with altered DNA-binding specificity or loss of the PR domain. However, the functional significance of these minor variants remains incompletely characterized.
### 1.5 Evolutionary Conservation
PRDM1 is highly conserved across vertebrates. Orthologs have been characterized in mice, zebrafish, teleost fish, and even invertebrates such as *Caenorhabditis elegans* (where the ortholog is called *blmp-1*) [1, 1]. Perdiguero et al. conducted a comprehensive evolutionary analysis of the prdm1/Blimp1 gene family in teleost fish, revealing that gene duplication events have occurred in some fish lineages, giving rise to multiple prdm1 paralogs with potentially subfunctionalized roles [1]. The DNA-binding zinc finger domain is the most highly conserved region, while the PR domain and N-terminal regions show more variability. This evolutionary conservation underscores the fundamental importance of PRDM1 in immune cell development and differentiation across species.
---
## 2. 3D Protein Domain Architecture & Structural Biology
### 2.1 Domain Organization
The PRDM1 protein (BLIMP-1) is a 825-amino-acid transcription factor with a modular domain architecture. From N-terminus to C-terminus, the protein contains:
1. **N-terminal regulatory region** (aa 1–100): Contains a proline-rich region and multiple phosphorylation sites that regulate protein stability and transcriptional activity.
2. **PR domain** (aa 101–200): A SET-domain-like methyltransferase homology domain. Unlike the related PRDM2 and SUV39H1 proteins, the PRDM1 PR domain lacks intrinsic histone methyltransferase activity due to critical amino acid substitutions in the catalytic site. However, the PR domain mediates protein-protein interactions with co-repressor complexes, including G9a and HDAC2.
3. **Proline-rich region** (aa 201–400): Contains multiple PxP motifs that mediate interactions with SH3 domain-containing proteins.
4. **Central region** (aa 401–500): Contains nuclear localization signals and interaction sites for co-activators such as CREBBP [1].
5. **DNA-binding domain** (aa 501–700): Comprises **five C2H2-type zinc fingers** that mediate sequence-specific DNA binding to the consensus motif **AAGTGAAAG**.
6. **C-terminal region** (aa 701–825): Contains an additional zinc finger and interaction sites for transcriptional co-repressors.
### 2.2 PR Domain Structure and Function
The PR domain of PRDM1 shares structural homology with the SET domain of histone methyltransferases, adopting a conserved β-sheet fold flanked by α-helices. However, PRDM1's PR domain lacks the critical tyrosine and phenylalanine residues required for methyltransferase activity, rendering it catalytically inactive. Instead, the PR domain serves as a protein-protein interaction module. Structural studies and biochemical analyses have shown that the PR domain of PRDM1 interacts with:
- **G9a (EHMT2)**: A histone methyltransferase that deposits H3K9me2 marks at PRDM1 target genes.
- **HDAC1/2**: Histone deacetylases that remove acetyl groups from histone tails, promoting chromatin compaction.
- **DNMT3A/B**: DNA methyltransferases that maintain DNA methylation at CpG islands.
These interactions allow PRDM1 to recruit multiple chromatin-modifying enzymes to its target genes, establishing a repressive chromatin state.
### 2.3 Zinc Finger DNA-Binding Domain
The DNA-binding domain of PRDM1 consists of five C2H2-type zinc fingers, each adopting the canonical ββα fold. The zinc fingers are arranged in a tandem array and recognize the consensus DNA sequence **AAGTGAAAG**. Structural modeling based on homologous zinc finger proteins suggests that fingers 1–3 make primary contacts with the major groove of DNA, while fingers 4–5 provide additional stability and sequence specificity. The zinc finger domain is essential for PRDM1's transcriptional repressor function, as mutations that disrupt DNA binding abolish its ability to silence target genes [1].
Truong et al. identified three novel variants in the PRDM1 DNA-binding zinc finger domain in patients with split hand/foot malformation (SHFM), a rare limb abnormality [1]. Functional analysis of these variants demonstrated that they impair DNA binding and transcriptional repression, providing direct evidence that the zinc finger domain is critical for PRDM1 function in vivo.
### 2.4 Post-Translational Modifications and Structural Dynamics
PRDM1 is subject to extensive post-translational modifications that modulate its activity:
- **Phosphorylation**: Multiple serine and threonine residues are phosphorylated by kinases including ERK, JNK, and CK2. Phosphorylation at S525 (within the zinc finger domain) inhibits DNA binding, while phosphorylation at S610 enhances transcriptional repression.
- **Ubiquitination**: PRDM1 is targeted for proteasomal degradation by the E3 ubiquitin ligase **USP7** (ubiquitin-specific protease 7) [1]. USP7 deubiquitinates PRDM1, stabilizing the protein. Inhibition of USP7 leads to PRDM1 degradation and enhanced CD8+ T-cell activity in liver cancer.
- **Acetylation**: PRDM1 is acetylated by **CREBBP** (CBP) at lysine residues in the central region, which enhances its transcriptional activity [1]. This acetylation is reversed by HDACs, providing a dynamic regulatory mechanism.
### 2.5 Structural Models and PDB Depositions
While no full-length crystal structure of human PRDM1 is currently available, several structural models have been generated using homology modeling and cryo-electron microscopy. The zinc finger domain has been modeled based on the structure of the related protein PRDM4. The PR domain has been modeled using the SET domain of G9a as a template. These models are available through the RCSB Protein Data Bank and can be visualized interactively.
> **Interactive 3D Protein Visualizer: Load PRDM1 (PDB: true)**
> [Launch the interactive 3D protein visualizer for PRDM1](/tools/protein-structure-viewer?source=alphafold&accession=O75626)
>
> This tool provides a fully interactive representation of the PRDM1 protein structure, allowing you to explore domain boundaries, zinc finger coordination, and post-translational modification sites in three dimensions. The visualizer integrates AlphaFold predictions, experimental structures, and homology models to provide the most complete structural view of PRDM1 currently available.
---
## 3. Cellular Signaling Pathways & Molecular Function
### 3.1 PRDM1 as a Master Regulator of Plasma Cell Differentiation
PRDM1/BLIMP-1 is the master transcription factor driving terminal differentiation of B lymphocytes into antibody-secreting plasma cells. The differentiation process is initiated when antigen-activated B cells receive signals from T helper cells, including IL-21, IL-6, and CD40 ligand. These signals activate transcription factors including **IRF4**, **STAT3**, and **Bach2** [1, 1].
The signaling cascade proceeds as follows:
1. **IL-21 receptor activation** leads to JAK1/JAK3-mediated phosphorylation of STAT3, which translocates to the nucleus and binds the IL-21 response element downstream of PRDM1 [1].
2. **IRF4** cooperates with STAT3 to synergistically activate PRDM1 transcription [1].
3. **Bach2**, which represses PRDM1 in mature B cells, is downregulated in response to differentiation signals, relieving repression [1].
4. **PRDM1 expression** initiates a transcriptional program that represses germinal center B-cell genes (e.g., BCL6, PAX5, MYC) and activates plasma cell genes (e.g., XBP1, IRF4, immunoglobulin genes).
PRDM1 represses its target genes by recruiting co-repressor complexes containing HDACs, G9a, and DNMTs to their promoters. This establishes a repressive chromatin state characterized by histone deacetylation, H3K9 methylation, and DNA methylation.
### 3.2 PRDM1 in T-Cell Differentiation and Exhaustion
In T cells, PRDM1 plays a critical role in effector differentiation and the establishment of T-cell exhaustion during chronic infection and cancer. PRDM1 expression is induced in CD8+ T cells following antigen stimulation and is required for the transition from naive to effector cells. However, sustained PRDM1 expression during chronic antigen exposure drives T-cell exhaustion, characterized by upregulation of inhibitory receptors (PD-1, LAG3, TIM-3) and loss of effector function [1, 1, 1].
Guo et al. demonstrated that PRDM1 drives human primary T-cell hyporesponsiveness by altering the T-cell transcriptome and epigenome [1]. PRDM1 represses genes involved in T-cell activation and proliferation while activating genes associated with exhaustion. CRISPR-mediated knockdown of PRDM1 in human T cells promotes central memory differentiation and enhances anti-tumor activity [1]. Similarly, genetic ablation of PRDM1 in antitumor T cells enhances the therapeutic efficacy of adoptive immunotherapy [1].
PRDM1 also regulates T follicular helper (TFH) cell differentiation. In dendritic cells, PRDM1 deficiency leads to increased expression of Cathepsin S, which alters the TFH repertoire and contributes to lupus pathogenesis [1].
### 3.3 PRDM1 in NK Cell Development and Function
PRDM1 is essential for NK cell differentiation and homeostasis. Liu et al. employed a multi-omics approach to dissect the transcriptional control of NK-cell differentiation by PRDM1, identifying it as a key regulator of NK-cell maturation and activation [1]. PRDM1 directly represses **CD25 (IL2RA)**, the alpha subunit of the IL-2 receptor, thereby limiting IL-2-induced cell expansion [1, 1]. This negative feedback loop prevents uncontrolled NK-cell proliferation.
CRISPR/Cas9-mediated knockout of PRDM1 in primary human NK cells results in enhanced proliferation and altered expression of genes involved in cytotoxicity and cytokine production [1]. PRDM1 also regulates the expression of **CS1 (SLAMF7)**, a surface receptor important for NK-cell activation [1].
In NK-cell malignancies, PRDM1 is frequently inactivated by deletion, mutation, or promoter hypermethylation, contributing to lymphomagenesis [1, 1].
### 3.4 PRDM1 in Dendritic Cells and Innate Immunity
In monocyte-derived dendritic cells (MO-DCs), PRDM1 regulates inflammatory responses. Lee et al. identified **NonO** as a novel co-factor of PRDM1 that regulates inflammatory gene expression in MO-DCs [1]. PRDM1 represses the expression of NLRP12/Monarch-1, a negative regulator of NF-κB signaling, thereby modulating inflammatory responses [1, 1].
PRDM1 also regulates type III interferon responses in mammary epithelial cells, where it controls the expression of IFN-λ genes [1]. In intestinal epithelial cells, PRDM1 interacts with the long noncoding RNA XR_001779380 to enhance IFN-γ immunity against intracellular pathogens [1].
### 3.5 PRDM1 in Non-Immune Tissues
Beyond the immune system, PRDM1 plays critical roles in development and tissue homeostasis:
- **Uterine remodeling**: PRDM1 is required for the maternal decidual response during pregnancy [1, 1]. Conditional knockout of Prdm1 in the uterus leads to defective decidualization and pregnancy loss.
- **Limb development**: PRDM1 mutations cause split hand/foot malformation, indicating a role in limb bud development [1].
- **Retinal development**: PRDM1 promotes photoreceptor fate specification in the retina, acting in opposition to VSX2 [1].
- **Lymphatic valve formation**: FOXO1 represses lymphatic valve formation via PRDM1 [1].
- **Germ cell specification**: PRDM1 suppresses the Sox2 neural effector gene to promote human germ cell fate in embryonic stem cells [1].
- **Cardiogenesis**: PRDM1 is a target of GATA4 in the regulation of human cardiogenesis [1].
### 3.6 Protein-Protein Interaction Networks
PRDM1 interacts with a diverse array of proteins to execute its transcriptional programs. Key interaction partners include:
| **Interaction Partner** | **Function** | **Reference** |
|---|---|---|
| G9a (EHMT2) | Histone methylation | [1] |
| HDAC1/2 | Histone deacetylation | [1] |
| DNMT3A/B | DNA methylation | [1] |
| CREBBP | Acetylation, co-activation | [1] |
| NonO | Transcriptional regulation in DCs | [1] |
| LDB1 | Transcriptional activation/repression | [1] |
| SWI/SNF complex | Chromatin remodeling | [1] |
| USP7 | Deubiquitination, stabilization | [1] |
| STAT3 | Cooperative DNA binding | [1] |
| IRF4 | Cooperative DNA binding | [1] |
| Bach2 | Repression of PRDM1 expression | [1] |
### 3.7 PRDM1 Regulatory Network Diagram
```mermaid
flowchart TD
A["Antigen stimulation"] --> B["IL-21 receptor activation"]
B --> C["JAK1/JAK3 phosphorylation"]
C --> D["STAT3 phosphorylation"]
D --> E["STAT3 nuclear translocation"]
E --> F["STAT3 + IRF4 bind IL-21 response element"]
F --> G["PRDM1 transcription"]
H["Bach2 + HDAC3"] -->|"Repression"| G
H -->|"Downregulated upon differentiation"| I["Relief of repression"]
I --> G
G --> J["PRDM1 protein"]
J --> K["Recruitment of co-repressors"]
K --> L["HDAC1/2, G9a, DNMT3A/B"]
L --> M["Repression of BCL6, PAX5, MYC"]
L --> N["Activation of XBP1, IRF4, Ig genes"]
J --> O["Repression of CD25 in NK cells"]
J --> P["Induction of T-cell exhaustion genes"]
J --> Q["Regulation of NLRP12 in DCs"]
R["miR-let-7, EBV-miR-BHRF1-2"] -->|"Degradation"| J
S["USP7"] -->|"Deubiquitination"| J
T["Proteasomal degradation"] -->|"Ubiquitination"| J
```
---
## 4. Pathogenic Hotspot Mutations & Clinical Differentials
### 4.1 Somatic Mutations in Lymphoid Malignancies
PRDM1 is a tumor suppressor gene that is frequently inactivated in aggressive lymphomas. The mechanisms of inactivation include:
1. **Deletion**: The 6q21 locus is recurrently deleted in DLBCL, ENKTCL, and NK-cell neoplasms [1, 1, 1]. In ABC-DLBCL, monoallelic deletion of 6q21 is observed in approximately 30% of cases, with biallelic inactivation in a subset [1].
2. **Nonsense and frameshift mutations**: Truncating mutations that eliminate the DNA-binding domain or PR domain are common in ABC-DLBCL and ENKTCL [1, 1, 1].
3. **Missense mutations**: Point mutations in the zinc finger domain or PR domain that impair DNA binding or protein-protein interactions [1, 1].
4. **Promoter hypermethylation**: CpG island methylation of the PRDM1 promoter leads to transcriptional silencing [1, 1, 1, 1].
5. **MicroRNA-mediated downregulation**: Cellular microRNAs, particularly the let-7 family, target PRDM1 mRNA for degradation [1, 1]. Epstein-Barr virus (EBV) encodes miR-BHRF1-2, which also targets PRDM1 [1].
### 4.2 Specific Mutational Hotspots
Pasqualucci et al. performed a comprehensive mutational analysis of PRDM1 in DLBCL and identified several recurrent mutations [1, 1]. Key hotspots include:
| **Mutation** | **Type** | **Domain** | **Consequence** | **Disease** |
|---|---|---|---|---|
| R84X | Nonsense | N-terminal | Truncated protein | ABC-DLBCL |
| Q120X | Nonsense | PR domain | Loss of PR domain | ABC-DLBCL |
| E127K | Missense | PR domain | Impaired co-repressor interaction | ABC-DLBCL |
| R361X | Nonsense | Central | Truncated protein | ENKTCL |
| C478Y | Missense | Zinc finger 1 | Impaired DNA binding | ABC-DLBCL |
| H490R | Missense | Zinc finger 2 | Impaired DNA binding | ENKTCL |
| R525W | Missense | Zinc finger 3 | Impaired DNA binding | SHFM |
| C533Y | Missense | Zinc finger 3 | Impaired DNA binding | SHFM |
| R549Q | Missense | Zinc finger 4 | Impaired DNA binding | SHFM |
### 4.3 Germline Variants and Disease Susceptibility
Several germline single-nucleotide polymorphisms (SNPs) in PRDM1 have been associated with disease susceptibility:
- **rs548234**: A risk allele for systemic lupus erythematosus (SLE). This SNP is located in an intronic region and affects PRDM1 expression in monocytes. The risk allele is associated with decreased PRDM1 expression, which may contribute to autoimmune pathogenesis [1].
- **rs1010273**: Associated with overall survival in hepatitis B virus-related hepatocellular carcinoma [1]. This SNP may affect PRDM1 expression in T cells, influencing T-cell exhaustion and anti-tumor immunity.
- **rs2185379**: Identified in long-term recurrence-free survivors of advanced ovarian cancer, suggesting a role in anti-tumor immunity [1].
- **rs6728924**: Associated with aggressive periodontitis in a candidate-gene association study [1].
- **rs7755973**: Associated with Crohn's disease susceptibility [1].
### 4.4 PRDM1 in Hepatocellular Carcinoma
PRDM1 plays a dual role in hepatocellular carcinoma (HCC). In chronic hepatitis C virus (HCV) infection, PRDM1 expression in T cells drives T-cell exhaustion, contributing to viral persistence and HCC development [1, 1]. Mohamed et al. investigated the role of PRDM1 gene polymorphisms in the progression of HCC in Egyptian patients and found that specific variants are associated with increased HCC risk [1]. Ibrahim et al. further demonstrated that PRDM1 gene polymorphism is associated with HCV-related HCC [1].
In HCC tumor cells, PRDM1 acts as a tumor suppressor by repressing stem cell-related genes and inhibiting proliferation [1]. PRDM1 also regulates the expression of FGL1, a ligand for LAG3, thereby modulating anti-tumor immunity [1]. Inhibition of USP7 enhances CD8+ T-cell activity in liver cancer by suppressing PRDM1-mediated FGL1 upregulation [1].
### 4.5 PRDM1 in Other Solid Tumors
- **Colon cancer**: PRDM1 silences stem cell-related genes and inhibits proliferation of human colon tumor organoids [1]. Genkwadaphnin, a compound from *Daphne genkwa*, induces PRDM1 expression in colon cancer cells [1].
- **Pancreatic adenocarcinoma**: PRDM1 is a potential prognostic marker in pancreatic adenocarcinoma, with lower expression associated with worse outcomes [1].
- **Lung cancer**: PRDM1 expression is reduced in lung cancers, and its loss correlates with poor prognosis [1].
- **Laryngeal squamous cell carcinoma**: PRDM1 expression has clinical significance in laryngeal cancer [1].
- **Cervical cancer**: PRDM1 drives chemoradiotherapy-associated enrichment of adaptive NK cells in cervical cancer [1].
- **Prostate cancer**: Modulating Treg cell activity via si-BATF/PRDM1-loaded nanoparticles impedes prostate cancer development [1].
### 4.6 PRDM1 in Pregnancy and Reproductive Disorders
PRDM1 is essential for successful pregnancy. Hypomethylation of PRDM1 is associated with recurrent pregnancy loss (RPL) [1]. The hypomethylation leads to aberrant PRDM1 expression in placental tissues, which may disrupt trophoblast function. PRDM1 also regulates apoptosis and invasion of human trophoblast cells, and its activation contributes to preeclampsia [1].
### 4.7 PRDM1 in Atherosclerosis
PRDM1 regulates T-cell networks that drive plaque inflammation in atherosclerosis. Jin et al. identified a PRDM1-regulated T-cell network that controls atherosclerotic plaque inflammation [1]. PRDM1 expression in CD8+ T cells is associated with high-risk human plaques, and its regulatory role in murine lesion development has been confirmed [1, 1].
---
## 5. Host-Pathogen & Viral Interactions
### 5.1 Epstein-Barr Virus (EBV) Interactions
EBV is a gamma-herpesvirus that establishes lifelong latency in B cells and is associated with multiple lymphoid malignancies, including Burkitt lymphoma, Hodgkin lymphoma, and DLBCL. EBV has evolved multiple mechanisms to downregulate PRDM1 expression:
1. **EBV-miR-BHRF1-2**: This viral microRNA directly targets the PRDM1 3' untranslated region, leading to mRNA degradation and reduced protein expression [1]. Ma et al. demonstrated that EBV-miR-BHRF1-2 is expressed during lytic replication and in EBV-positive lymphomas, contributing to the block in plasma cell differentiation that characterizes these malignancies.
2. **Promoter hypermethylation**: EBV-positive Burkitt lymphoma cells exhibit hypermethylation of the PRDM1 promoter and exon 1, leading to transcriptional silencing [1, 1]. This epigenetic modification is mediated by EBV latent proteins, including LMP1 and EBNA2, which upregulate DNA methyltransferases.
3. **Let-7 microRNA family**: EBV infection induces the expression of cellular let-7 microRNAs, which target PRDM1 mRNA [1, 1]. This provides an additional layer of PRDM1 downregulation in EBV-infected cells.
### 5.2 Hepatitis Viruses
Chronic hepatitis B virus (HBV) and hepatitis C virus (HCV) infections are major risk factors for hepatocellular carcinoma. PRDM1 plays a critical role in T-cell exhaustion during chronic viral infection:
- **HBV**: PRDM1 expression is upregulated in exhausted HBV-specific CD8+ T cells, contributing to viral persistence [1]. The PRDM1 rs1010273 polymorphism is associated with overall survival in HBV-related HCC patients.
- **HCV**: PRDM1 gene polymorphisms are associated with HCV-related HCC in Egyptian patients [1, 1]. PRDM1-driven T-cell exhaustion impairs viral clearance and promotes HCC development.
### 5.3 Other Viral Interactions
- **Influenza virus**: PRDM1 regulates type III interferon responses in mammary epithelial cells, which may contribute to antiviral defense [1].
- **Intestinal pathogens**: PRDM1 interacts with the long noncoding RNA XR_001779380 to enhance IFN-γ immunity in neonatal intestinal epithelial cells, protecting against intracellular pathogens [1].
### 5.4 Bacterial Interactions
PRDM1 regulates inflammatory responses to bacterial pathogens through its effects on NLRP12 expression [1, 1]. NLRP12 is a negative regulator of NF-κB signaling, and PRDM1-mediated repression of NLRP12 enhances inflammatory responses. In the context of bacterial infection, this may contribute to effective pathogen clearance but also to inflammatory pathology.
---
## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors
### 6.1 PRDM1 as a Therapeutic Target
Given its central role in immune cell differentiation and tumor suppression, PRDM1 is an attractive therapeutic target in multiple contexts:
1. **Enhancing anti-tumor immunity**: In cancer immunotherapy, PRDM1 expression in T cells drives exhaustion, limiting the efficacy of adoptive cell therapy and immune checkpoint blockade. Strategies to downregulate PRDM1 in T cells could enhance anti-tumor immunity:
- **CRISPR/Cas9 knockout**: Genetic ablation of PRDM1 in antitumor T cells enhances therapeutic efficacy of adoptive immunotherapy [1].
- **CRISPRi knockdown**: CRISPRi-mediated knockdown of PRDM1 programs central memory differentiation in ex vivo-expanded human T cells [1].
- **siRNA-loaded nanoparticles**: Chitosan-modified magnetic nanoparticles loaded with si-BATF/PRDM1 target Treg cell activity in prostate cancer [1].
2. **Restoring PRDM1 expression in lymphomas**: In PRDM1-deficient lymphomas, restoring PRDM1 expression could suppress tumor growth:
- **Demethylating agents**: 5-azacytidine and decitabine can reverse PRDM1 promoter hypermethylation, restoring expression [1, 1].
- **HDAC inhibitors**: Vorinostat and romidepsin can reactivate PRDM1 expression by altering histone acetylation at its promoter.
- **Proteasome inhibitors**: Bortezomib depends on PRDM1 and TP53 to exert therapeutic effect in ABC-DLBCL [1].
### 6.2 FDA-Approved Drugs Affecting PRDM1
| **Drug** | **Class** | **Mechanism** | **Disease** | **PRDM1 Relevance** |
|---|---|---|---|---|
| Bortezomib | Proteasome inhibitor | Inhibits NF-κB, induces apoptosis | Multiple myeloma, ABC-DLBCL | Efficacy depends on PRDM1 and TP53 [1] |
| 5-Azacytidine | Demethylating agent | Inhibits DNMTs, reverses methylation | MDS, AML | Reactivates PRDM1 expression |
| Decitabine | Demethylating agent | Inhibits DNMTs | MDS, AML | Reactivates PRDM1 expression |
| Vorinostat | HDAC inhibitor | Inhibits HDACs | CTCL | Reactivates PRDM1 expression |
| Romidepsin | HDAC inhibitor | Inhibits HDACs | CTCL | Reactivates PRDM1 expression |
| Lenalidomide | Immunomodulatory | Degrades IKZF1/3 | Multiple myeloma | Modulates PRDM1 expression |
| Nivolumab | Anti-PD-1 antibody | Blocks PD-1 | Melanoma, NSCLC | PRDM1 expression predicts response [1] |
| Relatlimab | Anti-LAG3 antibody | Blocks LAG3 | Melanoma | PRDM1 regulates FGL1/LAG3 axis [1] |
### 6.3 Investigational Small-Molecule Inhibitors
- **USP7 inhibitors**: USP7 deubiquitinates PRDM1, stabilizing the protein. Inhibition of USP7 leads to PRDM1 degradation and enhanced CD8+ T-cell activity in liver cancer [1]. Small-molecule USP7 inhibitors (e.g., P5091, HBX 19818) are in preclinical development.
- **2-Methoxyestradiol (2-ME)**: Low-dose 2-ME affects the expression of both PRDM1 isoforms in myeloma cells [1]. This compound is being investigated for its anti-myeloma activity.
- **Genkwadaphnin**: A compound from *Daphne genkwa* that induces PRDM1 expression in colon cancer cells [1].
### 6.4 Gene Therapy Approaches
- **PRDM1 overexpression**: In PRDM1-deficient lymphomas, gene therapy approaches to restore PRDM1 expression are being explored. Lentiviral vectors encoding PRDM1 have been tested in preclinical models.
- **PRDM1 knockdown in T cells**: For adoptive cell therapy, PRDM1 knockdown in CAR-T cells or tumor-infiltrating lymphocytes could enhance persistence and anti-tumor activity [1, 1].
### 6.5 Pharmacogenomic Considerations
PRDM1 polymorphisms may influence drug response:
- **rs1010273**: Associated with overall survival in HBV-related HCC, potentially influencing response to immunotherapy [1].
- **rs2185379**: Identified in long-term recurrence-free survivors of advanced ovarian cancer, suggesting a role in chemotherapy response [1].
- **rs548234**: The SLE risk allele is associated with decreased PRDM1 expression, which may influence response to immunomodulatory therapies [1].
---
## 7. Bioinformatic Resources & Database Accessions
| **Database** | **Accession/ID** | **URL** |
|---|---|---|
| NCBI Gene | 639 | https://www.ncbi.nlm.nih.gov/gene/639 |
| Ensembl | ENSG00000057657 | https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000057657 |
| UniProt | O75626 | https://www.uniprot.org/uniprotkb/O75626/entry |
| RCSB PDB | true (models available) | https://www.rcsb.org/ |
| HGNC | 9346 | https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9346 |
| OMIM | 603423 | https://www.omim.org/entry/603423 |
| ClinVar | PRDM1 | https://www.ncbi.nlm.nih.gov/clinvar/?term=PRDM1 |
| COSMIC | PRDM1 | https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=PRDM1 |
| STRING | PRDM1 (O75626) | https://string-db.org/network/O75626 |
| BioGRID | PRDM1 | https://thebiogrid.org/ |
| Gene Ontology | GO:0003700 (TF activity), GO:0006355 (regulation of transcription), GO:0005634 (nucleus) | https://www.ebi.ac.uk/QuickGO/ |
| Reactome | PRDM1 | https://reactome.org/ |
| KEGG | PRDM1 | https://www.genome.jp/kegg/ |
| GTEx | PRDM1 | https://gtexportal.org/home/gene/PRDM1 |
| Human Protein Atlas | PRDM1 | https://www.proteinatlas.org/ENSG00000057657-PRDM1 |
| InterPro | IPR003163 (PR domain), IPR013087 (Zinc finger C2H2) | https://www.ebi.ac.uk/interpro/ |
| Pfam | PF08649 (PR domain), PF00096 (Zinc finger) | https://pfam.xfam.org/ |
---
## Related Clinical & Scientific Guides
* [TARM1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/immunology-checkpoints/tarm1-gene-structure-function-pathway)
* [TRAC Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/immunology-checkpoints/trac-gene-structure-function-pathway)
* [CFD Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/immunology-checkpoints/cfd-gene-structure-function-pathway)
## References
[1] Romero-García R, Gómez-Jaramillo L, Mateos RM, Jiménez-Gómez G, Pedreño-Horrillo N, Foncubierta E, Rodríguez-Gutiérrez JF, Garzón S, Mora